Status:
COMPLETED
High-Density Lipoprotein (HDL) Modulation and Endothelial Function
Lead Sponsor:
University of Calgary
Collaborating Sponsors:
Heart and Stroke Foundation of Ontario
Conditions:
Atherosclerosis
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
It is well known that lowering low-density lipoprotein (LDL) (bad cholesterol) is beneficial for decreasing heart attacks and death. More recently, focus has been on trying to raise HDL (good) cholest...
Detailed Description
Purpose: To determine the incremental value of extended-release (ER) niacin in combination with high dose statin therapy on brachial endothelial function in subjects with coronary atherosclerosis. Hy...
Eligibility Criteria
Inclusion
- Aged 18-80 years
- Coronary artery disease
Exclusion
- HDL \> 1.10 (men), \> 1.30 (women)
- PCI within 30 days or CABG within 90 days
- Symptomatic congestive heart failure (CHF)
- Uncontrolled hypertension
- Gout or active gallbladder disease, liver disease or peptic ulcer disease
- Diabetes (or if Fasting blood sugar \> 7.0 then hemoglobin A1c \[HbA1C\] \> 6.1 is exclusionary)
- Abnormalities of complete blood count (CBC), creatinine or ALT
- Change in endothelial modulating drugs in the last month or use of niacin
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT00150722
Start Date
September 1 2005
End Date
August 1 2008
Last Update
November 10 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Foothills Medical Centre
Calgary, Alberta, Canada, T2N 2T9